Estrogen and the Brain: The Window That Might Matter for Alzheimer's

Two out of every three Americans living with Alzheimer’s are women. That number is what’s pushing a once-quiet question back into the center of menopause medicine: does the timing of estrogen loss have anything to do with the timing of dementia, and are the years around menopause a window when the brain is unusually responsive to estrogen?

The honest answer is that the evidence is genuinely mixed. There is a hypothesis with real biological grounding, and there is imaging that has changed how researchers think about the perimenopausal brain. There is also a long-term follow-up trial that found no cognitive benefit from menopausal hormone therapy a decade later, and no major medical society currently recommends estrogen for dementia prevention. Menopause hormone therapy is not FDA-approved to prevent or treat Alzheimer’s disease or any form of dementia, and this article is not an argument that it should be. What it is, instead, is the version of the conversation we have with women in their late 40s and early 50s who are watching a parent decline and asking what — if anything — that means for their own brains.

The 2025 Alzheimer’s Association Facts and Figures report estimates 7.2 million Americans age 65 and older are living with Alzheimer’s dementia, projected to nearly double to roughly 13 million by 2050. Of those currently affected, about 4.2 million are women and 3.0 million are men — close to two-thirds female.

Longer female life expectancy explains part of the gap, but not all of it. Even after adjusting for age, women carry a higher lifetime risk of Alzheimer’s, and the divergence appears to begin around the menopausal transition — exactly when ovarian estrogen production drops. That timing is what put the estrogen-and-the-brain conversation back on the table, and what makes it so easy to get wrong in either direction: oversold as brain-protection, or dismissed entirely because the trial data is imperfect.

Estrogen receptors are densely expressed in the hippocampus and prefrontal cortex — the same regions most affected in early Alzheimer’s disease. In animal and cell-culture models, estradiol supports synaptic plasticity, modulates the cholinergic system (the neurotransmitter pathway donepezil targets), reduces neuroinflammation, and influences neuronal glucose metabolism. These are mechanisms, not outcomes. The leap from “estrogen does things in brain tissue” to “estrogen prevents dementia in humans” is exactly the leap the data has not yet supported.

A 2024 PET imaging study from Dr. Lisa Mosconi’s group at Weill Cornell scanned 54 women across pre-, peri-, and postmenopausal stages. Estrogen receptor density in several brain regions actually increased during and after menopause — with higher density correlating to more reported cognitive and mood symptoms. The researchers interpreted this as a compensatory response: the brain trying to do more with less hormone. One implication they raised is that the “window of opportunity” for estrogen therapy may extend further past menopause than previously assumed. That is an interesting hypothesis. It is not yet a treatment recommendation.

The window phase hypothesis — sometimes called the critical window or timing hypothesis — proposes that estrogen’s effects on the brain are time-sensitive. Started near menopause onset, in women whose vascular and neural tissue is still healthy, estrogen may support brain function. Started a decade or more later, when atherosclerosis and other age-related changes have set in, the same hormone may not help and could carry risk.

The original Women’s Health Initiative Memory Study (WHIMS) enrolled women 65 and older — average participant in her early 70s. Combined estrogen-plus-progestin in this older cohort was associated with increased dementia risk, roughly 23 additional cases per 10,000 person-years versus placebo. That finding was the basis for the “probable dementia” warning the FDA removed in February 2026. What WHIMS could not answer is the question the timing hypothesis is really asking: what happens when therapy starts at 50, not 70?

The Kronos Early Estrogen Prevention Study (KEEPS) was designed to test the timing hypothesis. It randomized 727 recently menopausal women (average age ~52) to oral conjugated estrogen, transdermal estradiol, or placebo for four years. The 2015 KEEPS result: hormone therapy in this younger cohort did not improve cognition compared to placebo, but it also did not harm it.

The KEEPS Continuation Study, published in PLOS Medicine in November 2024, recontacted participants roughly 10 years after the trial — when most were in their early 60s — and reassessed cognition. It found no long-term cognitive effects of menopausal hormone therapy. Women who had received oral or transdermal estrogen performed similarly to placebo, and the strongest predictor of later performance was baseline cognition — not whether someone had been on hormones in their early 50s.

KEEPS Continuation is the best long-term data we have on women who started hormone therapy near menopause, and it shows neither cognitive benefit nor harm. The trial was modestly sized and primarily designed for cardiovascular markers, so it can’t rule out small effects in either direction. But it is a serious check on the strongest version of the brain-protection hypothesis: if estrogen at the right time prevents dementia, KEEPS Continuation did not detect it.

The Menopause Society (formerly NAMS) released its current Hormone Therapy Position Statement in 2022. On cognition, the language is unambiguous: “in the absence of more definitive findings, hormone therapy is not recommended at any age to prevent or treat a decline in cognitive function or dementia.” The statement preserves the timing distinction — initiating after age 65 was associated with increased dementia risk in WHIMS, while therapy started in the early postmenopausal period does not appear to harm cognition. But “does not appear to harm” is a meaningful step short of “prevents.” No major society — The Menopause Society, ACOG, the Endocrine Society, or the International Menopause Society — currently endorses estrogen for Alzheimer’s prevention.

The FDA’s February 2026 label change is consistent with this. The dementia warning came off because the blanket warning, anchored in older-onset data, no longer reflected the evidence on early-initiated therapy. The label did not add a prevention indication. MHT is not approved for brain health, cognitive performance, or dementia prevention, and the evidence does not currently support that use.

A typical Naya patient in this conversation is in her late 40s or early 50s, managing her own symptoms, watching a parent slip into mild cognitive impairment, and Googling at 2 a.m. The question she’s really asking isn’t always “should I take hormones for my brain.” It’s: “is there anything I can do now that I couldn’t have done at 70?”

The honest answer is that several things have stronger evidence than estrogen for late-life cognitive resilience: managing blood pressure in midlife, treating sleep apnea, addressing hearing loss, exercising regularly, maintaining cognitive and social engagement, and treating depression. These show up consistently in Lancet Commission dementia prevention modeling as the modifiable factors most likely to move risk. None require a hormone prescription.

Where the perimenopause hormone conversation belongs is narrower and more honest: if a woman is symptomatic — hot flashes, sleep disruption, mood changes, vaginal symptoms — and she is within the 10-year window the FDA label now recognizes, the conversation about hormone therapy is a symptom conversation that happens to take place in tissue that is also part of the brain-aging story. Better sleep, fewer night sweats, and stabilized mood are themselves modest contributors to cognitive function. That is a defensible reason to consider therapy. “Preventing Alzheimer’s” is not.

A thoughtful BHRT consult in this context treats the symptoms a woman actually has, not the disease she is afraid of. It reviews her personal and family history — cardiovascular risk, breast cancer history, clotting disorders, dementia risk factors — and weighs them honestly against potential benefit. It uses transdermal estradiol when there’s a vascular consideration, oral micronized progesterone when a uterus is present, and physiologic dosing rather than supraphysiologic. It revisits the decision over time. And it is candid about what the data does and does not yet support.

If you’ve been wondering whether perimenopause is a moment to think about your brain — not because hormones are a cure, but because midlife is when several of the levers for late-life cognitive health are most movable — that’s a conversation worth having with a clinician who will give you the careful version. Carolyn Pampalone, MSN, FNP-BC, has spent nearly two decades in women’s health and hormone care. You can talk it through at our Chatsworth or Santa Barbara clinics, or by telehealth across California.

Two California locations and statewide telehealth — click a card to view details, or call to schedule a consult.